非執行董事辭任 天大藥業有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，馮全明先生 （「馮先生」）因其他工作安排，所以辭任本公司非執行董事（「非執行董事」），自 2025年8月29日起生效。馮先生已確認，彼與董事會並無任何意見分歧，亦概無有 關彼辭任之事宜須提請本公司股東（「股東」）及香港聯合交易所有限公司（「香港聯 交所」）垂注。 董事會謹此對馮先生於其任職期間對本公司作出的寶貴貢獻表示摯誠謝意。 委任非執行董事 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全 部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 䢼ᑠ㟜ᕎ⟲ෑ〾՟ᆕ⒦̅ᕘ㡍Վ܉䢽 卻⫍֍ջ⽚厍00455卼 非執行董事的變更 1 朱先生於本公告日期前過去三年，概無在其證券於香港或海外任何證券市場 上市的公眾公司中擔任任何其他董事職務，彼現時亦無與本公司任何董事、監事、 高級管理人員或主要或控股股東概無任何關係。 除上文所披露者外，朱先生概無於本公司擔任任何其他職務；及概無於本公 司股份中持有香港法例第571章證券及期貨條例第XV部 ...

Group 1 - The core viewpoint of the news highlights the recent performance of Tian Da Pharmaceutical, which saw a stock price increase of 8.57% despite a decline in overall revenue and profit [1][2] - Tian Da Pharmaceutical's cumulative increase over the past month is 2.94%, and 3.55% year-to-date, underperforming the Hang Seng Index by 25.45% [2] - Financial data shows that as of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99%, and a net profit attributable to shareholders of -56.83 million yuan, a decrease of 154.07% [2] Group 2 - Currently, there are no institutional investment ratings for Tian Da Pharmaceutical [3] - The pharmaceutical and biotechnology industry has an average price-to-earnings (P/E) ratio of -2.05 times, with a median of 1.44 times; Tian Da Pharmaceutical's P/E ratio stands at -6.13 times, ranking 136th in the industry [3] - The company focuses on developing traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical sector [4] Group 3 - Tian Da Pharmaceutical is committed to building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards, and creating a new type of traditional Chinese medicine clinic [4] - The company utilizes advanced technologies such as big data and artificial intelligence to enhance its healthcare services and aims to expand its market presence both domestically and internationally [4] - The company has established marketing centers in Shenzhen and Zhuhai, and is gradually setting up branches in the US and Europe to support its international sales and brand development [4] Group 4 - A significant event reminder includes the disclosure of the mid-year report for the fiscal year 2025 on August 28, 2025 [5]

Group 1 - The company Tian Da Pharmaceutical (00455.HK) announced that it will hold a board meeting on August 28, 2025, to approve its interim results for the six months ending June 30, 2025 [1]

天大藥業有限公司 董事長兼董事總經理 方文權 謹啓 䢼ᑠ㟜ᕎ⟲ෑ〾՟ᆕ⒦̅ᕘ㡍Վ܉䢽 卻⫍֍ջ⽚厍00455卼 董事會會議日期 天大藥業有限公司（「本公司」）之董事會（「董事會」）謹此公佈，本公司將於2025年8 月28日（星期四）舉行董事會會議，以批准（其中包括）本公司及其附屬公司截至 2025年6月30日止六個月之中期業績。 代表董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 香港，2025年8月15日 於本公告日期，本公司之執行董事為方文權先生（董事長兼董事總經理）和呂文生 先生；非執行董事為鍾濤先生和馮全明先生；而獨立非執行董事則為林日輝先生、 趙崇康先生和冼彥芳博士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 天大藥業有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 III.已發行股份及/或庫存股份變動詳情 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00455 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | 本月底法定/註冊股本 ...

Company Overview - Tian Da Pharmaceutical focuses on the development of traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical industry [4] - The company is building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards, and creating a new type of traditional Chinese medicine clinic [4] - Tian Da Pharmaceutical utilizes advanced technologies such as big data and artificial intelligence to enhance its healthcare services and expand its market reach [4] Financial Performance - As of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99% [2] - The company recorded a net loss attributable to shareholders of 56.83 million yuan, a significant decline of 154.07% compared to the previous year [2] - The gross profit margin stood at 46.08%, with a debt-to-asset ratio of 33.9% [2] Market Position and Valuation - Tian Da Pharmaceutical's price-to-earnings (P/E) ratio is -4.73, ranking 138th in the industry, while the average P/E ratio for the pharmaceutical and biotechnology sector is 2.79 [3] - The company has underperformed the Hang Seng Index, with a cumulative decline of 20.12% this year, compared to the index's increase of 19.78% [2] Industry Context - The pharmaceutical and biotechnology industry has an average P/E ratio of 2.79, with a median of 6.7 [3] - Competitors in the industry include other pharmaceutical companies with varying P/E ratios, such as Jingxin Pharmaceutical at 0.86 and Dongrui Pharmaceutical at 3.03 [3]

Summary of Key Points Core Viewpoint - As of July 3, a total of 120 stocks reached their 52-week highs, indicating a strong market performance with notable leaders in the list [1]. Group 1: Top Performers - The top three stocks with the highest increase rates are: - 富誉控股 (Fuyou Holdings) at 90.76%, closing at 0.435 with a peak of 0.475 [1] - 信义能源 (Xinyi Energy) at 65.00%, closing at 1.200 with a peak of 1.980 [1] - 中国三三传媒 (China San San Media) at 42.86%, closing at 1.710 with a peak of 1.900 [1] Group 2: Additional Notable Stocks - Other notable stocks include: - ITE HOLDINGS at 34.21% increase, closing at 0.047 with a peak of 0.051 [1] - 星凯控股 (Xingkai Holdings) at 30.00%, closing at 0.480 with a peak of 0.650 [1] - 北京北辰实业股份 (Beijing Beichen Industrial) at 26.47%, closing at 0.940 with a peak of 1.290 [1] Group 3: Overall Market Trends - The overall trend shows a significant number of stocks achieving new highs, reflecting positive investor sentiment and market conditions [1].

Company Overview - Tian Da Pharmaceutical Co., Ltd. focuses on the development of traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical and healthcare sectors [4] - The company is building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards for Chinese medicinal materials, and creating a new type of Chinese medicine clinic called "Tian Da Clinic" [4] - Tian Da Pharmaceutical utilizes internet technology, big data, and artificial intelligence to integrate online and offline services, providing comprehensive healthcare services [4] Financial Performance - As of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99% [2] - The company recorded a net loss attributable to shareholders of 56.83 million yuan, a significant decline of 154.07% year-on-year [2] - The gross profit margin stood at 46.08%, with a debt-to-asset ratio of 33.9% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Tian Da Pharmaceutical [3] - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.44 times, with a median of 4.53 times [3] - Tian Da Pharmaceutical has a P/E ratio of -5.26 times, ranking 125th in the industry [3] - Comparatively, other companies in the sector have P/E ratios ranging from 0.72 times to 4.28 times [3] Recent Stock Performance - As of May 9, the Hang Seng Index increased by 0.4%, closing at 22,867.74 points [1] - Tian Da Pharmaceutical's stock price was 0.162 HKD per share, reflecting an increase of 8.0% with a trading volume of 2,000 shares and a turnover of 326 HKD [1] - Over the past month, the stock has experienced a cumulative decline of 10.71%, and a year-to-date decline of 11.24%, underperforming the Hang Seng Index's increase of 13.54% [2]

Regulatory Approvals - Tianda Pharmaceuticals received drug registration approval for "Nicorandil for Injection" from the National Medical Products Administration of China[15]. - Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. obtained drug registration approval for "Ibuprofen suspension" from the National Medical Products Administration of China[16]. - In 2024, the Group has received drug registration approvals for 4 new varieties, including pediatric drugs and a cardiocerebrovascular drug, which are expected to drive new growth momentum[75]. Corporate Social Responsibility - Tianda Pharmaceuticals was awarded the "Caring Company" logo for the fourth consecutive year by the Hong Kong Council of Social Service[13]. - Tianda Pharmaceuticals was recognized as a "Happy Company" under the "Happiness-at-Work Promotional Scheme" by the Promoting Happiness Index Foundation[12]. - The Group has conducted over 40 charity clinic sessions and organized numerous TCM-themed activities to promote TCM knowledge in the community[68]. Business Operations and Strategy - The company operates multiple TDMall locations, including in Jordan and Causeway Bay, enhancing its market presence[20][21]. - The Group's strategy includes the "Three Developments" focusing on Chinese medicine, innovative drugs, and quality healthcare services, aiming to consolidate core products and expand sales channels[39][42]. - The Group plans to launch three new products in 2025, enhancing its product pipeline and focusing on R&D for innovative drugs and consumer healthcare products[40][43]. - The Group opened its sixth TDMall globally and fifth in the Greater Bay Area in October 2024, aiming to establish it as an oncology treatment center[45]. - The Group aims to promote a collaborative development model of "drugs + medical services" to enhance the quality of the Chinese medicine business[46]. Financial Performance - The Group's total revenue for the Year was HK$329.9 million, a significant decline from HK$532.1 million in the Previous Financial Year, resulting in increased losses attributable to shareholders from HK$24.2 million to HK$61.4 million[52]. - Revenue from the Pharmaceuticals and medical technologies business was HK$283.9 million, down 39.7% from HK$470.7 million in the Previous Financial Year, primarily due to decreased demand for Tuoen® Ibuprofen and competitive pricing strategies affecting Tuoping® Valsartan capsules[82]. - The loss attributable to shareholders increased from HK$24.2 million to HK$61.4 million, reflecting the overall decline in business performance[89]. Governance and Management - The Company emphasizes corporate governance with various committees including Audit, Remuneration, and Risk Management[5]. - The Company has complied with the Corporate Governance Code during the year, except for the separation of the roles of Chairman and CEO[104]. - The Board consists of 6 male Directors and 1 female Director, including 2 Executive Directors and 3 Independent Non-executive Directors[110]. - The Company has established various committees, including the audit, nomination, remuneration, and risk management committees, primarily composed of INEDs[133]. - The Board has developed and reviewed policies related to Board diversity and shareholder communication[126]. Research and Development - The Group's R&D projects include one Class 1 TCM innovative drug, three Class 3 TCM new drugs, and twelve chemical generic drugs, indicating a rich R&D pipeline[74]. - The Group is focusing on the R&D of traditional Chinese medicine, aiming for stronger R&D, larger markets, and enhanced efficacy through technological advancements and resource growth[64]. - The Group is advancing the Phase II clinical trials of a Class 1 TCM innovative drug for chronic heart failure, highlighting its commitment to innovative medicine[76]. Market Challenges and Outlook - In 2024, the pharmaceutical market faced challenges due to economic uncertainty, with a focus on respiratory infection and antihypertensive drugs struggling to grow as inventory clearance continued post-pandemic[39][42]. - The Chinese medicine segment faced a decline in end-user demand due to the economic environment, impacting trading and production of Chinese medicinal materials[41][43]. - Future market demand is expected to improve as the economy recovers and national policies supporting the pharmaceutical industry are enhanced[46]. Human Resources - As of December 31, 2024, the Group employed approximately 701 employees across Hong Kong, the PRC, and Australia[99]. - The board currently consists of 6 male and 1 female directors, with female representation at approximately 48% at the workforce level[155].

Group 1 - Tian Da Pharmaceutical (00455.HK) closed at HKD 0.136 on April 10, down 12.26% from the previous trading day, with an intraday low of HKD 0.135, marking a new low in nearly a year [1] - The capital flow on that day showed a main inflow of HKD 0.000 million and an outflow of HKD 0.297 million, resulting in a net outflow of HKD 0.30 million [1] Group 2 - Tian Da Pharmaceutical focuses on developing traditional Chinese medicine (TCM) and aims to become a competitive player in drug research, medical technology, and health management [2] - The company is building a comprehensive TCM industry chain, establishing quality control standards for Chinese medicinal materials, and creating a new type of TCM clinic called "Tian Da Clinic" [2] - Tian Da Pharmaceutical leverages internet technology, big data, and artificial intelligence to integrate online and offline TCM services, providing convenient health services [2] - The product range includes traditional Chinese medicine, chemical drugs, biological products, health products, and medical devices, covering various therapeutic areas [2] - The company is expanding its market presence both domestically in China and internationally, with marketing centers in Shenzhen and Zhuhai, and subsidiaries in Hong Kong and Australia [2] - Tian Da Pharmaceutical aims to meet the growing healthcare demands by collaborating with quality partners and integrating advanced treatment technologies [2]